Recidief PC, fase III, gehypofractioneerd schema radiotherapie t.o.v. standaard gefractioneerd schema
mHSPC, fase III, ADT +/- duralotamide
mCRPC, abiraterone versus enzalutamide
Neuro-endocrien prostaatcarcinoom, fase Ib/II, immuuntherapie
mCRPC, fase III, MK-5684 + HRT vs abiraterone / enzalutamide
mCRPC, moleculaire screening
Solide tumoren, fase I, MET, MET kinase inhibitor
mCRPC, fase I, Lu-PSMA-617
Solide tumoren, EMA geregistreerde middelen
Solide tumoren, ‘actionable’ moleculaire target
Urologische tumoren
Formulier
